MONTELUCAST APPLICATION IN TREATMENT FOR BRONCHIAL ASTHMA OF VARIOUS SEVERITY

Occurrence of bronchial asthma is growing. The experts have proved its genetic and clinical heterogeneity. This is what also calls forth incomplete response to the conventional anti inflammatory medications. During asthma, dozens of various mediators take an active part in the pathogenesis of inflammation in the respiratory passages, including a set of c4, d4 and е4 leukotrienes, which causes contractions of the bronchi plain muscles. Among all the anti leukotriene medications ever studied for the sales in the Russian federation, the federal agencies approved of and registered zafirlukast and montelucast only. Montelucast is recommended in treatment for bronchial asthma of all the severity levels, as well as both as a medication to enhance the basic therapy and a medication for monotherapy, which is thanks to the data from a handful of multicentered, double, blind, placebo, controlled studies. The application of the peroral medications, montelucast in particular, may be a good alternative to the inhalant medications used among the patients with poor discipline and inhalation techniques (children, aged patients and etc.). When we speak of allergic rhinitis, montelucast application is essential to exclude polypragmasy, as well as for the initial asthma prevention.Key words: bronchial asthma, children, treatment, anti leukotrienes

MONTELUCAST APPLICATION IN TREATMENT FOR BRONCHIAL ASTHMA OF VARIOUS SEVERITY

Occurrence of bronchial asthma is growing. The experts have proved its genetic and clinical heterogeneity. This is what also calls forth incomplete response to the conventional anti inflammatory medications. During asthma, dozens of various mediators take an active part in the pathogenesis of inflammation in the respiratory passages, including a set of c4, d4 and е4 leukotrienes, which causes contractions of the bronchi plain muscles. Among all the anti leukotriene medications ever studied for the sales in the Russian federation, the federal agencies approved of and registered zafirlukast and montelucast only. Montelucast is recommended in treatment for bronchial asthma of all the severity levels, as well as both as a medication to enhance the basic therapy and a medication for monotherapy, which is thanks to the data from a handful of multicentered, double, blind, placebo, controlled studies. The application of the peroral medications, montelucast in particular, may be a good alternative to the inhalant medications used among the patients with poor discipline and inhalation techniques (children, aged patients and etc.). When we speak of allergic rhinitis, montelucast application is essential to exclude polypragmasy, as well as for the initial asthma prevention.Key words: bronchial asthma, children, treatment, anti leukotrienes

ACTIVATED ZINC PYRITHIONE APPLICATION FOR THE ATOPIC DERMATITIS AMONG CHILDREN: MECHANISM OF ACTION, CLINICAL EFFICIENCY

Atopic dermatitis is characterized by the chronic recurrent course and often complicated by the consecutive infection and requires an adequate and regular external treatment. This article is devoted to the overview of the key pharmacodynamic and clinical effects of the activated zinc pyrithione for the atopic dermatitis. The activated zinc pyrithione has an expressed, antiinflammatory, proapoptogenic, antifungal and antibacterial effect, owing to which it affects all the components of the atopic dermatitis pathogenesis. The research with nessed the high efficiency and safety of this medication for atopic dermatitis in children, which allows the researchers to classify it as the efficient non steroid medications for the external treatment for the atopic dermatitis among children.Key words: atopic dermatitis, treatment, activated zinc pyrithione, children

ACTIVATED ZINC PYRITHIONE APPLICATION FOR THE ATOPIC DERMATITIS AMONG CHILDREN: MECHANISM OF ACTION, CLINICAL EFFICIENCY

Atopic dermatitis is characterized by the chronic recurrent course and often complicated by the consecutive infection and requires an adequate and regular external treatment. This article is devoted to the overview of the key pharmacodynamic and clinical effects of the activated zinc pyrithione for the atopic dermatitis. The activated zinc pyrithione has an expressed, antiinflammatory, proapoptogenic, antifungal and antibacterial effect, owing to which it affects all the components of the atopic dermatitis pathogenesis. The research with nessed the high efficiency and safety of this medication for atopic dermatitis in children, which allows the researchers to classify it as the efficient non steroid medications for the external treatment for the atopic dermatitis among children.Key words: atopic dermatitis, treatment, activated zinc pyrithione, children

PIMECROLIMUS APPLICATION IN TREATMENT FOR ATOPIC DERMATITIS DURING LOCALIZATION OF THE SKIN RASH IN AREAS WITH THIN AND SENSITIVE SKIN

The lecture highlights the modern approaches to the therapy for atopic dermatitis among children and adults, as well as reviews the principles of the external therapy prescription with regards to the localization of the rush on the patient's skin. The authors presents the most important findings of pimecrolimus clinical tests, including the information on the cream efficacy and tolerance if applied to the skin on the face and other parts with thin and sensitive skin.Key words: atopic dermatitis, children, adults, therapy, pimecrolimus

SUBLINGUAL SPECIFIC IMMUNOTHERAPY IN THE TREATMENT OF HAY FEVER CAUSED BY TREE POLLEN IN CHILDREN

The results of the investigation of effectiveness and safety of sublingual allergen specific immunotherapy (slit) with tree pollen mixture for hay fever treatment in children are presented in the article. 42 children 4 to 18 years old with hay fever (allergic rhinoconjunctivitis, pollen asthma) were included in the study. Birch, alder and hazel pollen sensitization was proved by skin prick test (positive in 5 patients and strongly positive in 37). 2 courses of slit out of flowering season were conducted in every child. Total dose of allergen was 43321 ± 73 PNU (3990 to 120 000 PNU) after 1st course of slit, and 93 850 ± 128 PNU (8750 to 249 000 PNU) after 2nd course. Effectiveness of the 1st course of slit was 3,5 points out of 4,0 and of the 2nd course — 3,8 points. Disease remission was registered in 59,5% patients after the 1st course of slit and in 83,3% patients after the 2nd course. Local side effects (tongue and throat itching, nausea and o edema of lips) and systemic side effects (rhinorrhea, eye itching, fatiguability and bronchospasm) of mild severity did not lead to treatment cessation. Slit is highly effective and safe method for hay fever treatment in children.Key words: pollen sensitization, sublingual allergen specific immunotherapy, children

SUBLINGUAL SPECIFIC IMMUNOTHERAPY IN THE TREATMENT OF HAY FEVER CAUSED BY TREE POLLEN IN CHILDREN

The results of the investigation of effectiveness and safety of sublingual allergen specific immunotherapy (slit) with tree pollen mixture for hay fever treatment in children are presented in the article. 42 children 4 to 18 years old with hay fever (allergic rhinoconjunctivitis, pollen asthma) were included in the study. Birch, alder and hazel pollen sensitization was proved by skin prick test (positive in 5 patients and strongly positive in 37). 2 courses of slit out of flowering season were conducted in every child. Total dose of allergen was 43321 ± 73 PNU (3990 to 120 000 PNU) after 1st course of slit, and 93 850 ± 128 PNU (8750 to 249 000 PNU) after 2nd course. Effectiveness of the 1st course of slit was 3,5 points out of 4,0 and of the 2nd course — 3,8 points. Disease remission was registered in 59,5% patients after the 1st course of slit and in 83,3% patients after the 2nd course. Local side effects (tongue and throat itching, nausea and o edema of lips) and systemic side effects (rhinorrhea, eye itching, fatiguability and bronchospasm) of mild severity did not lead to treatment cessation. Slit is highly effective and safe method for hay fever treatment in children.Key words: pollen sensitization, sublingual allergen specific immunotherapy, children

ПРИМЕНЕНИЕ МОНТЕЛУКАСТА В ЛЕЧЕНИИ БРОНХИАЛЬНОЙ АСТМЫ РАЗНОЙ СТЕПЕНИ ТЯЖЕСТИ

Occurrence of bronchial asthma is growing. The experts have proved its genetic and clinical heterogeneity. This is what also calls forth incomplete response to the conventional anti inflammatory medications. During asthma, dozens of various mediators take an active part in the pathogenesis of inflammation in the respiratory passages, including a set of c4, d4 and е4 leukotrienes, which causes contractions of the bronchi plain muscles. Among all the anti leukotriene medications ever studied for the sales in the Russian federation, the federal agencies approved of and registered zafirlukast and montelucast only. Montelucast is recommended in treatment for bronchial asthma of all the severity levels, as well as both as a medication to enhance the basic therapy and a medication for monotherapy, which is thanks to the data from a handful of multicentered, double, blind, placebo, controlled studies. The application of the peroral medications, montelucast in particular, may be a good alternative to the inhalant medications used among the patients with poor discipline and inhalation techniques (children, aged patients and etc.). When we speak of allergic rhinitis, montelucast application is essential to exclude polypragmasy, as well as for the initial asthma prevention.Key words: bronchial asthma, children, treatment, anti leukotrienes.Распространенность бронхиальной астмы растет, доказана ее генетическая и клиническая гетерогенность. Этим обусловлен, в том числе, и неполный ответ на традиционные противовоспалительные препараты. В патогенезе воспаления в дыхательных путях при астме участвуют десятки различных медиаторов, в том числе комплекс лейкотриенов C4, D4 и Е4 вызывающий сокращение гладких мышц бронхов. Среди всех исследованных антилейкотриеновых препаратов для продажи в РФ зарегистрированы только зафирлукаст и монтелукаст. Монтелукаст рекомендован для применения при всех степенях тяжести бронхиальной астмы и как средство усиления базисной терапии, и как препарат монотерапии, что основано на данных многочисленных многоцентровых двойных слепых плацебо контролируемых исследований. Применение пероральных препаратов, в частности, монтелукаста, может стать альтернативой ингаляционным средствам у больных с низкой дисциплиной и плохой техникой ингаляций (дети, пациенты пожилого возраста и др.). Применение монтелукаста при аллергическом рините важно для исключения полипрагмазии и первичной профилактики астмы. Ключевые слова: бронхиальная астма, дети, лечение, антилейкотриены.(Педиатрическая фармакология. – 2007;4(4):58-62)

АКТИВИРОВАННЫЙ ЦИНКА ПИРИТИОН ПРИ АТОПИЧЕСКОМ ДЕРМАТИТЕ У ДЕТЕЙ. МЕХАНИЗМ ДЕЙСТВИЯ, КЛИНИЧЕСКАЯ ЭФФЕКТИВНОСТЬ

Atopic dermatitis is characterized by the chronic recurrent course and often complicated by the consecutive infection and requires an adequate and regular external treatment. This article is devoted to the overview of the key pharmacodynamic and clinical effects of the activated zinc pyrithione for the atopic dermatitis. The activated zinc pyrithione has an expressed, antiinflammatory, proapoptogenic, antifungal and antibacterial effect, owing to which it affects all the components of the atopic dermatitis pathogenesis. The research with nessed the high efficiency and safety of this medication for atopic dermatitis in children, which allows the researchers to classify it as the efficient non steroid medications for the external treatment for the atopic dermatitis among children.Key words: atopic dermatitis, treatment, activated zinc pyrithione, children.Атопический дерматит имеет хроническое рецидивирующее течение, часто осложняется вторичной инфекцией и требует адекватной и постоянной наружной терапии. Данная статья посвящена обзору основных фармакодинамических и клинических эффектов активированного пиритиона цинка при атопическом дерматите (АтД). Активированный пиритион цинка обладает выраженным противовоспалительным, проапоптогенным, противогрибковым и антимикотическим действием, благодаря чему воздействует на все компоненты патогенеза АтД. Проведенные исследования свидетельствуют о высокой эффективности и безопасности этого препарата при АтД у детей, что позволяет отнести его к эффективным нестероидным средствам для наружной терапии АтД у детей. Ключевые слова: атопический дерматит, лечение, активированный пиритион цинка, дети. (Педиатрическая фармакология. – 2009;6(2):67-71

CLINICAL EFFICIENCY OF ZINC PYRITHIONE TO TREAT ATOPIC DERMATITIS IN CHILDREN

Atopic dermatitis is one of the most widespread children’s diseases, it has a chronic recurrent clinical course, may be often complicated with the secondary infection. This necessitates the choice of a medication to impact all stages of the disease process with a high safety profile. This digest is devoted to activated zinc pyrithione. Overall, currently available data make it possible to state that this agent is one of the most effective and safest products to be used for a local therapy of atopic dermatitis in children. Key words: atopic dermatitis, activated zinc pyrithione, childre